Why the study?
Does compliance with pharmacological thromboprophylaxis protocols prevent hospital-acquired venous thromboembolic disease in hospitalized patients?
Does compliance with pharmacological thromboprophylaxis protocols prevent hospital-acquired venous thromboembolic disease in hospitalized patients?
A substantial proportion of patients who develop hospital-acquired VTE do not receive adequate pharmacological prophylaxis despite established hospital protocols, highlighting the need for better compliance monitoring.
Adherence gaps in most HAVTED cases warrant compliance monitoring; leaves open whether better prophylaxis prevents hospital-acquired VTE.
Objective: To study hospital-acquired venous thromboembolic disease (HAVTED) and the relationship between its incidence and compliance with thromboprophylaxis protocols. Methods: For the past eight years, specialty-specific protocols for VTE prophylaxis have been in operation throughout this hospital. Patients developing radiologically proven VTE either as inpatients or within 12 weeks of discharge were identified from a register. Patients were categorized according to risk as per the Scottish Intercollegiate Guidelines Network (SIGN) guidelines. The use of pharmacological prophylaxis for VTE was recorded. Results: Over a period of 24 months, 98 patients had radiologically proven HAVTED. Of 44 categorized as high risk, 17 (39%) had received prophylaxis. Corresponding figures for 50 at medium risk and four at low risk were 16 (32%) and three (75%), respectively. The overall incidence of HAVTED averaged two per 1000 inpatient discharges varying between 0.2 in General Medicine and 6.6 in Trauma Orthopaedics. The mean additional cost of treating a case of HAVTED was estimated at £3,000. Conclusion:Audit of radiological investigations of VTE showed that 18% of all cases were hospital acquired. A hospital policy of thromboprophylaxis may reduce but does not eliminate HAVTED. A substantial proportion of patients with HAVTED had not received prophylaxis. The possibility of a further reduction in incidence of HAVTED with potential saving in morbidity, mortality and cost is highlighted. The implementation and efficacy of thromboprophylaxis protocols should be monitored.
No takes yet. Share an insight, caveat, or question.
Carrim et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: